· We obtained the exclusive right to develop and commercialize Edivoxetine(EDP 125) in Greater China, South Korea, Japan, Malaysia, Singapore, Vietnam, Indonesia and Thailand.
· We completed the acquisition of the product rights of FPN in China and the Netherlands from GSK.